中文

← All funding rounds

Accipiter Bio

Also known as Accipiter Biosciences

United StatesProtein designSeattle, United StatesPrivate

Website · accipiterbio.com ↗

Designs proteins from scratch, with its own computational methods and high-throughput experiments, that combine several mechanisms in one stable molecule, including agonists that activate several pathways on the same cell; its pipeline is in immunology and oncology.

Disclosed total$12.7M
Rounds on record1
Latest round$12.7MSeed · 2025-11-06
Last stated valuationNone stated
Investors named8
Research on recordNone yet

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date2026$12.7M
Closed round

No research by this company is on the record yet.

Rounds and research, on one timeline

  1. 2025-11-06Seed
    Round

    $12.7M

    For: build its immunology and oncology pipeline, further enhance its computational platform and advance up to two programmes to pre-IND

    Models and platformToward the clinic

    The release names the co-lead as Flying Fish Partners and the founders' prior work only as a team (Seagen, Merck, Neoleukin Therapeutics, the University of Washington's Institute for Protein Design).

    Co-lead · TakedaCo-lead · Flying FishColumbus Venture PartnersCercano CapitalWashington Research FoundationAlexandria InvestmentsPack VenturesArgonautic Ventures

    On the deal: Heather Gorham (Principal and Accipiter board member; spoke for the co-lead in the announcement, Flying Fish, joins the board)

    Announced by the company · markets.financialcontent.com ↗On the timeline →

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

Its investors also backed

Other companies on this page whose rounds name the same investor.